Physician profile
Amanda S Ayers
NPI 1528268182
$2,840.43
in general payments reported to CMS, 2019-2025
26 companies · $23.43 in 2025
The $23.43 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $42.08 · 2021: $194 · 2022: $254 · 2023: $356 · 2024: $1,767 · 2025: $23.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,500 · Food and Beverage: $487 · Travel and Lodging: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,500.00 |
| Food and Beverage | $486.74 |
| Travel and Lodging | $159.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,549.15 | 2019-2024 | |
| Axonics, INC. | $244.61 | 2022-2024 | Axonics |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.81 | 2019-2023 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $128.34 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $125.47 | 2022-2023 | Linzess |
| Dentsply Ih Ab | $57.30 | 2024 | Navina Rectal Catheter Set Regular |
| Boston Scientific Corporation | $51.65 | 2019-2023 | |
| Ferring Pharmaceuticals INC. | $46.06 | 2021-2022 | |
| Olympus America INC. | $37.79 | 2023 | Endoclot Phs, Single Use Electrosurgical Snare Sd-400 |
| Bayer Healthcare Pharmaceuticals INC. | $34.99 | 2022 | |
| Medtronic, INC. | $29.69 | 2023 | Interstim |
| Kci USA, INC. | $28.59 | 2019 | |
| Celgene Corporation | $25.13 | 2023 | Zeposia |
| Thd America, INC. | $25.00 | 2020-2022 | |
| Novo Nordisk INC | $23.43 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $22.31 | 2019 | |
| Intercept Pharmaceuticals, INC. | $21.31 | 2023 | Ocaliva |
| Abbvie INC. | $20.29 | 2023 | Rinvoq |
| Regeneron Healthcare Solutions, INC. | $19.32 | 2023 | Dupixent |
| Ardelyx, INC. | $18.61 | 2023 | Ibsrela |
| Redhill Biopharma INC. | $17.97 | 2022 | |
| Janssen Biotech, INC. | $17.70 | 2023 | Remicade, Stelara, Simponi |
| Shire North American Group INC | $17.70 | 2019 | |
| Masimo Corporation | $17.00 | 2021 | |
| Novum Pharma, LLC | $16.77 | 2019 | |
| Gilead Sciences, INC. | $16.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.